Last reviewed · How we verify
NCT04925843: FIB_TOF
Fibrinogen and Intraoperative Bleeding in Liver Transplant
trial in End Stage Liver DIsease in 612 participants. Completed in 10 January 2022.
10 January 2022
Quick facts
| Lead sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 612 |
| Start date | 15 July 2019 |
| Primary completion | 10 January 2022 |
| Estimated completion | 10 January 2022 |
| Sites | 1 location across Canada |
Conditions studied
- End Stage Liver DIsease — all drugs for End Stage Liver DIsease →
- Liver Transplant; Complications — all drugs for Liver Transplant; Complications →
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Who can join
18 and older, any sex, with End Stage Liver DIsease or Liver Transplant; Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Liver transplantation is the only treatment for end-stage liver disease. It is a high-risk surgery that can cause heavy intraoperative bleeding. Bleeding and transfusions of blood products are themselves associated with several postoperative complications. Few data have suggested beneficial interventions that can decrease this bleeding. Such interventions are necessary in order to improve these patients' outcomes. In order to better understand the potential therapeutic targets, a better comprehension of the variables associated with such bleeding is essential. Several previous studies have demonstrated a weak association between usual clotting times and bleeding in this population. However, few studies have evaluated the association between the concentration of fibrinogen and bleeding in this population. The primary objective of this study is to assess the association between preoperative serum fibrinogen concentration and the volume of intraoperative bleeding. The secondary objective is to assess the association between preoperative serum fibrinogen concentration and the number of red blood cell units transfused during the intraoperative and immediate postoperative periods. The hypothesis of the study is that a low concentration of preoperative fibrinogen will be associated with an increase in intraoperative bleeding and red blood cell transfusions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04925843
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End Stage Liver DIsease
Currently open trials in the same condition.
- NCT05205954 — HepHospital: A Pilot Trial of a Hepatology Home Hospital Intervention for Patients With Advanced Liver Disease · NA · recruiting
- NCT06455280 — A Study of SIPLIZUMAB in AILD and LT Patients · Phase 1 · recruiting
- NCT06136221 — Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease · NA · recruiting
- NCT05260268 — Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant · NA · recruiting
- NCT05477277 — Adverse Outcomes and Mortality in Liver Transplant · NA · recruiting
Other Centre hospitalier de l'Université de Montréal (CHUM) trials
Trials by the same sponsor.
- NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
- NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
- NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
- NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
- NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04925843 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
- Last refreshed: 29 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04925843.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing